Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.
February 05, 2026 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET Access the webcast here Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or...
January 29, 2026 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design Appointments strengthen...
January 27, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Filing four provisional patent applications...underscores our relentless drive to protect and expand our groundbreaking proenzyme technology
January 22, 2026 09:00 ET | Source: Kaida Biopharma

Kaida BioPharma Appoints Co-Founder Dr. Stella K. Vnook as Chairperson of the Board

Appointment aligns Board leadership with Company’s transition to clinical-stage development and advancement of KAD-101 for platinum-resistant ovarian cancer Company advancing KAD-101, a...
January 13, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Shareholder Update

In this update, Mr. Nathanielsz highlights the significant progress achieved during 2025 and outlines the Company’s ambitious plans for 2026.
January 08, 2026 08:45 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support key regulatory milestones for Ameluz PDT in both indicationsAK and acne...
January 05, 2026 09:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company...
December 22, 2025 07:00 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Our findings demonstrate that PRP exerts multifaceted effects specifically over the cancer associated fibroblasts (CAFs) population and tumor cells.
December 16, 2025 16:15 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces $1.51 Million Private Placement

CHICAGO, IL, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies...